The Mayo Clinic Cancer Center has opened a new clinical study today using a vaccine strain of the measles virus to attack recurrent glioblastoma multiforme (GBM). The Mayo Clinic's research has grown from the most basic laboratory science to the sophisticated therapy being tested today on several tumor types, including GBM, recurrent ovarian cancer and multiple myeloma.

The study is designed to test the safety of the virus for the treatment of gliomas and enable monitoring of anti-tumor activity. Eligible candidates for the therapy will have GBM that has progressed after surgery and radiation therapy. They also must be immune to measles, either having had the disease or been vaccinated against it.

Many cancer cells, including glioblastoma cells, overexpress a specific protein which allows tumor cells to avoid destruction by the immune system. Strains of the measles virus seek out this protein and enter the tumor. When it enters the virus begins to spread infecting nearby tumor cells which increases cancer cell death.

Back in the1970's it was noted that measles infections could cause regression of cancer tumors in children. Nothing was done about studying this phenomenon until late in the 1990's when the Mayo Clinic Cancer Center's Molecular Medicine Program began looking into it. The researchers are now also looking at ways to use the measles virus to combat breast and pancreatic cancer, they already have plans to open up another clinic study this fall to test the effectiveness of a version of the measles virus on multiple myeloma.